Extended Data Fig.4. Elicitation of BG505-WT binders through rapid immunization and long GCs.
a, Experiment schematic. Two repeats were compiled. Mice per group varied.
b, BGC cells in iLNs.
c, Percent of VRC01gHL BGC cells that are BG505-WT probe binding.
d, Representative plots from each group of endogenous BGC stained with BG505-WT probe. Percent of GC and total endogenous (CD45.2+) BGC cells positive for BG505-WT probe.
e, Representative flow plots of two alternate probe panels run for 7 week animals. Endogenous and VRC01gHL BGC cells from same animal stained with either 001428-WT and 001428-CD4bs.KO or 001428-WT alone.
a-e, All groups contain mice from both of two experimental repeats. Final n= 8,7,9,10 left to right for groups plotted.
f, Schematic of additional group analyzed at 7 weeks. Plotted with same data in Figure 4.f, group X has all three immunogens delivered cotemporally resulting in 30 μg protein and 2x dose ISCOM. Analyzed alongside groups described in in Figure 4a, e.
g-j, Experiment described in Figure 4f-h.
g, Total BGC cells at week 8 in iLNs.
h,Total endogenous (CD45.2+) BGC cells that are BG505-WT probe positive with LOD as brown dotted line at 50 cells/animal.
i, Total VRC01 BGC cells.
j, Percent of VRC01gHL BGC cells that are BG505-WT probe binding.
g-j, Table denotes immunization weeks and contents. All immunizations included adjuvant. Immunizations match previous amounts with the exception: where (2x) or two antigens are listed final amounts of antigen and adjuvant are doubled and mice were given final immunizations at week 6 with analysis at week 7. Multiple experiments were compiled, and not all experiments included all groups. Compiled experiments include groups from Figure 5a (diamonds) and Figure 4a.
Means and SD are represented as bars. Kruskal-Wallis uncorrected test; not significant (NS), P > 0.05; * P < 0.05; ** P< 0.01; *** P < 0.001; **** P < 0.0001. For Figure.4.